PTC Therapeutics (PTCT) PT Lowered to $53 at JPMorgan, 'Late Stage Assets Remain Significantly Underappreciated'

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/10/2026

1. SPY
2. USO
3. NET
4. SAIL
5. SJM
6. SPCX
7. ETR
8. AMZN
9. MU
10. DVN

Go back to PTC Therapeutics (PTCT) PT Lowered to $53 at JPMorgan, 'Late Stage Assets Remain Significantly Underappreciated'

CHMP Delivers Opinion on Translarna™ for Conversion to Full Authorization

September 15, 2023 6:00 AM EDT

- Conference call to be held at 8:45 am EDT -

SOUTH PLAINFIELD, N.J., Sept. 15, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a negative opinion on the conversion of the conditional marketing authorization to full marketing authorization of Translarna (ataluren) for the treatment of nonsense... More